TY - JOUR
TI - Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: A pilot study
AU - Tsavaris, N.
AU - Kosmas, C.
AU - Vadiaka, M.
AU - Zonios, D.
AU - Papalambros, E.
AU - Papantoniou, N.
AU - Margaris, H.
AU - Zografos, G.
AU - Rokana, S.
AU - Retalis, G.
AU - Koufos, C.
JO - Journal of Pain and Symptom Management
PY - 2003
VL - 26
TODO - 3
SP - 849-854
PB - ELSEVIER SCIENCE INC 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN - 0885-3924
TODO - 10.1016/S0885-3924(03)00283-5
TODO - amifostine;  antidiarrheal agent;  diphenoxylate;  fluorouracil;  folinate calcium;  loperamide;  octreotide, adult;  advanced cancer;  aged;  anorexia;  article;  blood toxicity;  bone marrow toxicity;  cancer combination chemotherapy;  chemotherapy induced emesis;  clinical trial;  colorectal cancer;  controlled clinical trial;  controlled study;  diarrhea;  disease severity;  dose response;  drug effect;  drug efficacy;  drug safety;  drug tolerability;  female;  human;  hypotension;  incidence;  low drug dose;  major clinical study;  male;  mucosa inflammation;  nausea;  pilot study;  prophylaxis;  treatment outcome
TODO - Fifty-two consecutive patients with advanced colorectal cancer who developed persistent diarrhea following chemotherapy with 5-fluorouracil despite dose reduction were treated with amifostine 800, 500 or 150 mg/m 2. The administered dose of 5-fluorouracil was significantly greater during amifostine treatment. Amifostine 800 mg/m2 was associated with complete elimination of diarrhea, but 76.3% of patients developed infusion-related hypotension. At a dose of 500 mg/m2, diarrhea was significantly reduced and milder compared with baseline and the incidence of hypotension was 54.2%. At the lowest dose of amifostine, 17.1% of patients developed Grade 1 diarrhea, a significant reduction over baseline, and hypotension occurred in 25.2% of patients. Treatment with amifostine also improved mucositis but had no effect on the relatively mild nausea and vomiting due to 5-fluorouracil. In this study, amifostine reduced the incidence and severity of diarrhea associated with 5-fluorouracil in patients with advanced colorectal cancer, with acceptable efficacy at a reduced dose that offered better tolerability. © 2003 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
ER -